Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Gene
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
08:30am, Thursday, 11'th Jun 2026
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
07:30am, Monday, 08'th Jun 2026
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 202
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 29'th May 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living w
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
07:30am, Tuesday, 12'th May 2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseas
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
12:21am, Thursday, 07'th May 2026
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
07:35pm, Wednesday, 06'th May 2026
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.06 per share a year ago.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
04:05pm, Wednesday, 06'th May 2026
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 mil
Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast
01:12am, Monday, 27'th Apr 2026
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast t
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy” by Analysts
02:15am, Sunday, 22'nd Mar 2026
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings repor
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 20'th Mar 2026
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
07:30am, Monday, 16'th Mar 2026
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise
Why Zevra Therapeutics Stock Zoomed 21% Higher Today
05:57pm, Tuesday, 10'th Mar 2026
It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
10:52am, Tuesday, 10'th Mar 2026
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC m
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
04:42am, Tuesday, 10'th Mar 2026
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
